H.R.7407 amends the Federal Food, Drug, and Cosmetic Act by adding two new prohibited acts. First, it makes it unlawful to introduce or deliver for introduction into interstate commerce any product marketed as a dietary supplement if that product does not satisfy the statutory definition of a dietary supplement (section 201(ff)).
Second, it bars marketing or distribution of dietary supplements that were prepared, packed, or held with the assistance of — or at the direction of — a person debarred under section 306.
The bill also updates the FD&C Act’s import exclusion and seizure provisions so Customs and FDA can refuse admission at the border and seize or condemn goods that violate the new prohibitions. The change sharpens enforcement tools against borderline or dangerous “supplements” (the short title cites tianeptine) and shifts compliance risk onto manufacturers, contract packers, importers, and distributors who rely on third‑party or debarred personnel.
At a Glance
What It Does
The bill adds two prohibited acts to section 301 of the FD&C Act: (1) selling or shipping products marketed as dietary supplements that do not meet the statutory definition of a dietary supplement; and (2) selling or shipping dietary supplements prepared/packed/held with the assistance or direction of a person debarred under section 306. It also amends import exclusion and seizure provisions to cover those new violations.
Who It Affects
Manufacturers, contract packers, and private‑labelers of dietary supplements; importers and distributors who bring supplements into interstate commerce; firms that engage debarred individuals or debarred entities in production, storage, or packing; and FDA/Customs for enforcement at the border and in the market.
Why It Matters
The bill turns marketing‑classification disputes and contractor vetting into per se unlawful acts enforceable through import refusals and seizures. That raises the stakes for companies selling novel ingredients or using third‑party manufacturers and gives FDA clearer statutory grounds to remove certain supplements from commerce.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
H.R.7407 draws two bright lines. The first makes it a statutory prohibited act to introduce into interstate commerce any product that is advertised or otherwise marketed as a dietary supplement but does not in fact meet the statutory definition under section 201(ff).
In practice that means FDA can treat a mismatch between how a product is marketed and what the statute contemplates as more than a labeling infraction — it becomes a direct prohibition on distribution.
The second line targets who handles the physical product: the bill forbids introduction into interstate commerce of dietary supplements that were prepared, packed, or held with the assistance of, or at the direction of, any person already debarred under section 306. Section 306 is the agency’s existing debarment authority for individuals or entities following certain misconduct; this bill connects that status to supply‑chain eligibility and makes use of debarred labor or direction an independent violation.To make those prohibitions actionable the bill amends the import exclusion language and the seizure and condemnation provisions of the FD&C Act.
Customs can refuse admission at the border where products violate the new paragraphs, and FDA can seize or condemn domestic shipments on the same grounds. Those changes turn classification and contractor‑vetting failures into immediate enforcement triggers, not just regulatory compliance issues.Operationally, companies that develop, package, import, or market supplements will need to tighten two practices: (1) legal and labeling review to ensure a product actually fits the statutory ‘‘dietary supplement’’ definition before marketing it as such; and (2) due diligence on contract manufacturers, warehouses, and third‑party service providers to confirm none are debarred or operating under the direction of a debarred person.
Customs and FDA field offices will also need to interpret ‘‘marketed as’’ and prove assistance or direction by debarred persons when making detention or seizure decisions.
The Five Things You Need to Know
The bill adds paragraph (jjj) to section 301: introducing into interstate commerce any product marketed as a dietary supplement that does not meet the section 201(ff) definition is a prohibited act.
The bill adds paragraph (kkk) to section 301: introducing into interstate commerce a dietary supplement prepared, packed, or held using the assistance of, or at the direction of, a person debarred under section 306 is a prohibited act.
Section 801(a) (import exclusions) is amended so Customs can refuse admission of imports that violate the new paragraphs (jjj) or (kkk), allowing single‑point border enforcement.
Section 304 (seizure and condemnation) is amended to authorize seizure and condemnation of products in violation of the new paragraphs, giving FDA an express statutory hook for market removal.
The bill’s short title explicitly references tianeptine — signaling congressional focus on that compound and similar products marketed as supplements but considered dangerous or outside the statutory supplement definition.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title — 'Prohibiting Tianeptine and Other Dangerous Products Act of 2026'
This is the bill’s caption. Including tianeptine in the short title signals the policy intent and the kinds of products Congress has in view, but the operative provisions do not list substances; they rely on the legal definition of dietary supplement and on debarment status to capture problematic supply chains.
Creates two new prohibited acts
Paragraph (jjj) makes it unlawful to introduce or deliver for introduction into interstate commerce any product marketed as a dietary supplement that fails to meet the statutory definition in section 201(ff). Paragraph (kkk) makes it unlawful to introduce or deliver a dietary supplement that was prepared, packed, or held with assistance or direction from a person debarred under section 306. Those are affirmative, per‑se prohibitions rather than permissive regulatory standards.
Extends import refusal to the new prohibited acts
The bill updates the import exclusion clause so Customs may refuse admission of foreign shipments that violate paragraphs (jjj) or (kkk). That gives border authorities explicit statutory authority to stop such products at entry — not just after importation — which shortens the enforcement timeline and places initial compliance burden on importers and brokers.
Adds the new prohibitions to seizure and condemnation authority
The seizure and condemnation statute is revised to include products in violation of the new paragraphs among items that FDA can seize and condemn. This aligns domestic enforcement tools with the import exclusion changes and makes it easier for FDA to remove offending products from interstate commerce without relying solely on injunctions or labeling cases.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Consumers concerned about dangerous or misbranded products — they gain stronger statutory protection because products marketed as supplements that fall outside the legal definition can be removed from the market.
- FDA and Customs and Border Protection — both agencies get clearer statutory authority to refuse, seize, and condemn products tied to the new prohibited acts, simplifying enforcement decisions at the border and in the domestic market.
- Compliant supplement companies — legitimate manufacturers and brand owners benefit from reduced unfair competition from products that falsely claim supplement status, and from clearer grounds to ask for enforcement against noncompliant rivals.
- Public health and clinical stakeholders — healthcare providers and poison centers may see downstream benefits if dangerous non‑supplement products are taken off the market more quickly.
Who Bears the Cost
- Companies marketing novel ingredients or format innovations — firms that sell products on the margins of the statutory definition face higher legal risk and may need to reclassify or reformulate offerings.
- Contract manufacturers, packers, and warehouses — they must verify that no debarred person assisted or directed operations, imposing new onboarding, screening, and documentation costs.
- Importers and distributors — the possibility of immediate import refusals or seizures raises supply‑chain risk and may increase costs for testing, documentation, and customs compliance.
- Small and emerging supplement businesses — startups with limited compliance capacity could be disproportionately burdened by the need to demonstrate statutory fit and perform due diligence on third‑party service providers.
Key Issues
The Core Tension
The bill pits rapid public‑health protection against the risk of chilling legitimate commerce: it empowers immediate removal of dangerous or mischaracterized products but does so by creating per‑se violations tied to marketing language and contractor status, raising the chances of overreach, supply‑chain disruption, and litigation absent clear implementing guidance and administrative capacity.
The bill trades a blunt enforcement tool for clarity and speed, but it leaves important implementation questions unresolved. ‘‘Marketed as a dietary supplement’’ is a fact‑intensive phrase that courts and field staff will have to interpret: packaging, promotional materials, and distribution channels could all factor into whether a product falls under paragraph (jjj). Absent regulatory guidance, firms may face uncertain enforcement lines and increased litigation over classification.
The provision barring use of debarred persons raises proof and scope issues. The statute forbids products prepared, packed, or held with the assistance of a debarred person or at their direction — but the bill does not define ‘‘assistance’’ or set a materiality threshold.
That could sweep in contract relationships where a debarred individual provides limited, indirect support (e.g., remote consulting or legacy management oversight). It also shifts burden onto manufacturers and importers to vet labor and contractors, a nontrivial task in complex, global supply chains.
Finally, the expanded import and seizure authorities will require additional Customs and FDA resources and field guidance to avoid arbitrary or inconsistent enforcement at ports and during inspections.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.